Our present study suggests that cardiomyocyte GCH1 is a potent therapeutic target for DCM, and developing novel 26S proteasome inhibitors with specificity towards cardiac GCH1 may be useful for the clinic treatment of DCM. This evidence concerns the gene GCH1 and familial dilated cardiomyopathy.